These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 20231558)

  • 1. ACP Journal Club. Review: Tamoxifen, raloxifene, and tibolone prevent primary invasive breast cancer but increase risk for adverse outcomes.
    Melnikow J
    Ann Intern Med; 2010 Mar; 152(6):JC3-4. PubMed ID: 20231558
    [No Abstract]   [Full Text] [Related]  

  • 2. Tamoxifen, raloxifene and tibolone decrease risk of invasive breast cancer in healthy women but increase risk of thromboembolism (tamoxifen, raloxifene), endometrial cancer (tamoxifen) or stroke (tibolone).
    Vogel VG
    Evid Based Med; 2010 Aug; 15(4):122. PubMed ID: 20682726
    [No Abstract]   [Full Text] [Related]  

  • 3. The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial.
    Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Wolmark N
    Clin Breast Cancer; 2002 Jun; 3(2):153-9. PubMed ID: 12123540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
    Ganz PA; Land SR
    Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer risk management.
    Reeder JG; Vogel VG
    Clin Breast Cancer; 2007 Dec; 7(11):833-40. PubMed ID: 18269772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene.
    Lee WL; Cheng MH; Chao HT; Wang PH
    Taiwan J Obstet Gynecol; 2008 Mar; 47(1):24-31. PubMed ID: 18400579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis.
    Grann VR; Jacobson JS; Whang W; Hershman D; Heitjan DF; Antman KH; Neugut AI
    Cancer J Sci Am; 2000; 6(1):13-20. PubMed ID: 10696733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer.
    Dimitrakakis C; Keramopoulos D; Vourli G; Gaki V; Bredakis N; Keramopoulos A
    Climacteric; 2005 Dec; 8(4):342-51. PubMed ID: 16390769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The endocrine prevention of breast cancer.
    Howell A
    Best Pract Res Clin Endocrinol Metab; 2008 Aug; 22(4):615-23. PubMed ID: 18971122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raloxifene use in clinical practice: efficacy and safety.
    Goldstein SR; Duvernoy CS; Calaf J; Adachi JD; Mershon JL; Dowsett SA; Agnusdei D; Stuenkel CA
    Menopause; 2009; 16(2):413-21. PubMed ID: 19092711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.
    Bevers TB
    J Natl Compr Canc Netw; 2007 Sep; 5(8):719-24. PubMed ID: 17927929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ.
    Vogel VG; Costantino JP; Wickerham DL; Cronin WM
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):495S-501S. PubMed ID: 12538506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
    Lee WL; Chao HT; Cheng MH; Wang PH
    Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ACP Journal Club. Use of paroxetine during tamoxifen therapy for breast cancer was associated with increased breast-cancer and all-cause mortality.
    Hillner BE
    Ann Intern Med; 2010 Jun; 152(12):JC6-13. PubMed ID: 20547895
    [No Abstract]   [Full Text] [Related]  

  • 15. The STAR (Study of Tamoxifen and Raloxifene) trial in West Virginia.
    Jubelirer SJ; Crowell EB
    W V Med J; 2000; 96(6):602-4. PubMed ID: 11194089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoprevention in postmenopausal women.
    Rastogi P
    Menopause; 2008; 15(4 Suppl):810-5. PubMed ID: 18596603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.
    Barrett-Connor E; Mosca L; Collins P; Geiger MJ; Grady D; Kornitzer M; McNabb MA; Wenger NK;
    N Engl J Med; 2006 Jul; 355(2):125-37. PubMed ID: 16837676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent results from clinical trials using SERMs to reduce the risk of breast cancer.
    Vogel VG
    Ann N Y Acad Sci; 2006 Nov; 1089():127-42. PubMed ID: 17261762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoprevention of breast cancer.
    Dalton RR; Kallab AM
    South Med J; 2001 Jan; 94(1):7-15. PubMed ID: 11213947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ACP Journal Club. Review: Erythropoiesis-stimulating agents targeted to higher hemoglobin levels increase risk for adverse outcomes in CKD.
    Hsu CY
    Ann Intern Med; 2010 Nov; 153(10):JC5-3. PubMed ID: 21079210
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.